TITLE

Foe Turned Friend

AUTHOR(S)
Overdorf, Jason; Spring, Silvia
PUB. DATE
March 2007
SOURCE
Newsweek (Atlantic Edition);3/5/2007 (Atlantic Edition), Vol. 149 Issue 10, p43
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article states that generic drug manufactures in India are teaming up with larger pharmaceutical companies. The Indian pharmaceutical companies previously have been involved in legal battles with the larger pharmaceutical companies for copying their drugs. The partnerships are due in part to western pharmaceutical companies releasing fewer novel drugs than they previously have and Indian drug patent laws becoming more restrictive. The development of the drug balaglitazone is discussed.
ACCESSION #
24230431

 

Related Articles

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generic Rx Has Majority of Market, IMS Study Shows. Toth, Wendy // SN: Supermarket News;3/17/2008, Vol. 56 Issue 11, p25 

    The article focuses on a study which found that generic prescriptions account for a large part of the pharmaceutical market in the U.S. According to the study, 65 percent of all U.S. prescriptions dispensed are filled with generics. It also noted that as a number of big-name drugs are set to...

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Price Indices of Drugs and the Switching to New Drugs: Two Empirical Examples. Gerdtham, U-G.; Johannesson, M.; Gunnarsson, B.; Marcusson, M.; Henriksson, F. // PharmacoEconomics;1998, Vol. 13 Issue 1, p71 

    Standard price indices may not account for the price decrease that results when patients switch to pharmaceutical products for which their demand-reservation price exceeds the price of the new product. In a similar way, standard price indices may not account for the price increase that results...

  • Generic Drugs: More Than Meets the Eye? Not all drugs are created equal. Be aware of these potential differences. Shovlin, Joseph P. // Review of Cornea & Contact Lenses;Nov2015, p6 

    The author offers his insight on issues concerning generic drugs in the U.S. He highlights potential risks for patients who shop online for generic drugs as well as issues regarding drug's approval and manufacturing process and new signs and symptoms related to generics. He also discusses the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics